5α-reductase-IN-1 is a potent inhibitor of the enzyme 5α-reductase. This compound is primarily employed in research studies to investigate its potential efficacy in treating patterned alopecia. It is commonly used in combination with minoxidil, a well-known treatment for hair loss.
(Rac)-PF-998425 is a potent, selective, nonsteroidal antagonist of the androgen receptor (AR), with IC50 values of 26 nM and 90 nM in AR binding and cellular assays, respectively. This compound shows promise for investigating androgenetic alopecia.
5-Androstenetriol, a steroid and active metabolite of dehydroepiandrosterone (DHEA), demonstrates significant therapeutic effects. Administered at 0.75 mg 25 g body weight, it mitigates radiation-induced mortality and facilitates hematopoietic recovery from surviving stem cells in mice. Moreover, a dosage of 40 mg kg enhances survival rates in rats subjected to surgical trauma-induced sepsis. Additionally, elevated urinary levels of 5-androstenetriol are observed in women suffering from androgenic alopecia.